Definium Therapeutics, Inc.

Market Cap

$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$23.02+$9.38 (+68.77%)

Jun 8, 2026

52W High $24.5952W Low $6.49

Company Details

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety ...

CEO

—

IPO Date

Jul 11, 2022

Website

definiumtx.com

Key Metrics TTM

Revenue

- YoY

Net Income

-$238M

EPS (Diluted)

Free Cash Flow

-$144M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 7, 2026

FY 2025

Feb 26, 2026

Q4 2025

Feb 26, 2026

Q3 2025

Nov 6, 2025

Q2 2025

Jul 31, 2025

Revenue & Profitability

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee